Showing 4721-4730 of 5659 results for "".
- Botox Cosmetic Turns 20!https://practicaldermatology.com/news/botox-cosmetic-turns-20/2461158/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- Lack of Options for Darker Skin Types Hinder Use of Tinted Sunscreenshttps://practicaldermatology.com/news/tinted-sunscreens-lack-options-for-darker-skin-hindering-use/2461156/The lack of tinted sunscreen options for darker skin tones may discourage many people from using these products. This is the main message from a new analysis of consumer preferences of over-the-counter tinted sunscreen products. Sixty-two percent of tinted sunscreen products are only av
- Aquavit Submits NDA for New Neurotoxinhttps://practicaldermatology.com/news/aquavit-submits-nda-for-new-neurotoxin/2461141/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- Opzelura Shows Benefit in 52-Week Phase 3 Vitiligo Studyhttps://practicaldermatology.com/news/opzelura-shows-benefit-in-52-week-phase-3-vitiligo-study/2461139/New 52-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Incyte's topical JAK1/JAK2 inhibitor ruxolitinib cream (Opzelura™) in adolescent and adult patients with nonsegmental vitiligo show that twice daily application was
- Janssen Launches VISIBLE Study of PsO in People of Colorhttps://practicaldermatology.com/news/janssen-launched-visible-study-of-pso-in-people-of-color/2461121/The Janssen Pharmaceutical Companies of Johnson & Johnson has initiated VISIBLE, a first-of-its-kind, large-scale prospective clinical study dedicated to people of color living with moderate to severe plaque and/or scalp psoriasis (PsO). VISIBLE will further evaluate the efficacy an
- Jeune Aesthetics Announces Positive Clinical Phase 1 Efficacy Results for KB301https://practicaldermatology.com/news/jeune-aesthetics-announces-positive-clinical-phase-1-efficacy-results-for-kb301/2461119/Aesthetics, Inc.’s KB301 demonstrated promise in proof-of-concept in the Phase 1 PEARL-1 study. Specifically, Cohort 2 of this trial evaluated KB301 for the improvement of fine lines and skin texture in the lower and upper cheek, and for improvement in skin thickness in
- DefenAge Receives Two US Patents For Melasma and Hair Growthhttps://practicaldermatology.com/news/defenage-receives-two-us-patents-for-melasma-and-hair-growth/2461118/The US Patent and Trademark Office has granted two new patents to Defanage Skincare for the use of Defensin-molecules for topical treatment of hair loss in skin affected by alopecia and of the hyperpigmented lesions of melasma: &l
- Residents of Distinction Recognized at Maui Dermhttps://practicaldermatology.com/news/residents-of-distinction-honored-at-maui-derm/2461111/Sydney Liang, MD, a second-year resident at New York University, was awarded the Overall Grand Prize and was one of five dermatology residents recognized by DermMentors™ as part of the 11th Annual dermMentors™ Resident of Distinction Award™ for 2022.
- It's Grant Season: NEA Announces 2022 Eczema Research Grant Cyclehttps://practicaldermatology.com/news/its-grant-season-nea-announces-2022-eczema-research-grant-cycle-1/2461109/The National Eczema Association's (NEA) 2022 research grant cycle is now open, with awards totaling $760,000. Applications must be received by June 1, 2022, at 5 p.m. PDT, and recipients will be announced in October 2022. As the largest private nonprofi
- Novan, Inc. Acquires EPI Healthhttps://practicaldermatology.com/news/novan-inc-acquires-epi-health/2461106/EPI Health is now a Novan Company. The EP Group today announced the acquisition of EPI Health, LLC by Novan, Inc. EPI Health is a leading company in the US dermatology sector with an established sales force and commercial team with existing, deep market relationships across the de